1. Explore principles of treatment sequencing in different case scenarios while utilizing novel antibody drug conjugates in the context of rapidly evolving approved therapies.
  2.  Consider multidisciplinary considerations of managing potential toxicities of therapies and adaptation to women's normal physiologies and endocrinological needs.
  3.  Apply new concepts of HER2 low disease in the clinical setting.
Session date: 
08/30/2022 - 7:00am to 8:00am CDT
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Nan Chen, MD, Sarah Shubeck, MD, Adam DuVall, MD, MPH